Yasmeen Rahimi
Stock Analyst at Piper Sandler
(1.4)
# 1500
Out of 5,305 analysts
109
Total ratings
33.75%
Success rate
12.71%
Average return
Main Sectors:
Top Industries:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
SLNO Soleno Therapeutics | Maintains: Overweight | 93 145 | 73.32 | 97.76% | 2 | Apr 24, 2025 | |
EWTX Edgewise Therapeutic... | Maintains: Overweight | 51 51 | 14.87 | 242.97% | 4 | Apr 2, 2025 | |
LXRX Lexicon Pharmaceutic... | Maintains: Overweight | 10 6 | 0.71 | 745.07% | 2 | Mar 7, 2025 | |
AVTX Avalo Therapeutics | Initiates Coverage On: Overweight | 48 | 4.78 | 904.18% | 1 | Feb 28, 2025 | |
PRTA Prothena Corp | Maintains: Overweight | 94 110 | 9.69 | 1035.19% | 2 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 93 | 32.35 | 187.48% | 1 | Jan 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 75 | 8.36 | 797.13% | 1 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 7 | 0.77 | 809.09% | 1 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 52 26 | 7.78 | 234.19% | 2 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 37 37 | 17.45 | 112.03% | 2 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 26 26 | 1.38 | 1784.06% | 2 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 68 20 | 2.17 | 821.66% | 2 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 28 28 | 1.11 | 2422.52% | 3 | Jul 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 97 97 | 32.42 | 199.2% | 4 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 270 270 | 35.99 | 650.21% | 3 | Jul 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 76 | 21.15 | 259.34% | 1 | Jun 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 25 25 | 5.08 | 392.13% | 3 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 30 | 13.55 | 121.4% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Overweight | 6 12 | 3.88 | 209.28% | 2 | May 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 31 36 | 65.52 | -45.05% | 2 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 9 | 0.64 | 1306.25% | 1 | Apr 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 180 180 | 17.88 | 906.71% | 2 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 15 | 0.96 | 1462.5% | 1 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 336 | 326.66 | 2.86% | 3 | Mar 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 7 16 | 3.19 | 401.57% | 2 | Mar 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 80 | 20.69 | 286.66% | 1 | Feb 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 33 33 | n/a | n/a | 5 | Feb 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 250 40 | n/a | n/a | 3 | Dec 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 58 93 | 23.84 | 290.1% | 3 | Oct 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 65 | 16.8 | 286.9% | 1 | Oct 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 28 57 | 14.67 | 288.55% | 2 | Oct 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 67 | 3.15 | 2026.98% | 1 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 35 | 44.48 | -21.31% | 3 | Jul 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 138 200 | n/a | n/a | 3 | Apr 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 22 | 0.33 | 6566.67% | 1 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 41 | n/a | n/a | 1 | Mar 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 87 | 5.59 | 1456.35% | 3 | Feb 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 75 175 | 5.42 | 3128.78% | 4 | Jan 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 18 13 | n/a | n/a | 2 | Oct 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 73 | n/a | n/a | 1 | Aug 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 50 72 | 40.44 | 78.04% | 3 | Jun 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 63 27 | 1.46 | 1749.32% | 1 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 54 19 | 6.96 | 172.99% | 2 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 50 | 1.2 | 4066.67% | 1 | Nov 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 40 | 0.49 | 8063.27% | 1 | Aug 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 18 | 0.4 | 4400% | 1 | Jun 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 220 45 | n/a | n/a | 2 | Jun 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 68 81 | n/a | n/a | 3 | Mar 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 77 | 12.91 | 496.44% | 1 | Aug 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 420 | 10.51 | 3896.19% | 1 | Aug 26, 2020 |